ClinicalTrials.gg
RecruitingNCT04262687POCHIUpdated Aug 18, 2023

Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

A Phase 2 interventional study of Capecitabine and Oxaliplatin in Colorectal Cancer Metastatic, High Immune Infiltrate and Microsatellite Stable, sponsored by Federation Francophone de Cancerologie Digestive. Recruiting at 88 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Federation Francophone de Cancerologie Digestive · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies testing pembrolizumab in Colorectal Neoplasms — 5 open to participants now, 10 under way, 1 of them phase 3. pembrolizumab · Colorectal Neoplasms.

Planned enrollment
14th of 33
55 · median 45
Started
2021
with 3 others
Phase 2
19 of 33
4 open now
Registered
22nd of 33
by date
Lead sponsor
1 of 33
Federation Francophone de Cancerologie Digestive

Among the 33 studies testing pembrolizumab in Colorectal Neoplasms, this one is the 14th largest by planned enrollment, is one of 4 that started in 2021, is one of 19 in phase 2, and was the 22nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 33 studies testing pembrolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing pembrolizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called CRC with microsatellite stability (MSS). Other CRC, i.e. 15%, are "microsatellite unstable" (MSI) with deficient DNA Mismatch-Repair system (dMMR). These latter are characterised by generation of many neo-antigens, which result in a high anti-tumour immune response and a high peri- and/or intra-tumour lymphocyte infiltration (TIL). Investigators recently showed, with a prospectively validated immune score, that 14% of localised MSS/pMMR CRC are also highly infiltrated by CD3+ lymphocytes. This same immune score has made it possible to measure high lymphocyte infiltration in hepatic metastases, in particular, in patients treated with XELOX/FOLFOX.

Pembrolizumab, an anti-PD1 monoclonal antibody (programmed death-1) is an immune checkpoint inhibitor (ICI) of PD1/PD-L1 axis, recently approved in many cancers. Anti-PD1 antibodies have recently been reported as being very effective in patients with dMMR metastatic CRC (mCRC). In the study by Le DT et al. pMMR mCRC did not seem to benefit from anti-PD1 antibodies. However, it is possible that 20% of pMMR mCRC with a high CD3+ infiltrate in the tumour may be a subgroup of pMMR mCRC sensitive to ICI, as is the case for dMMR mCRC. Lastly, immunogenic cell death induced by chemotherapy, such as oxaliplatin, can increase the efficacy of ICI.

The prognostic value of lymphocyte infiltrate has been demonstrated in CRC by several teams. However, no validated test is used in routine clinical practice. Previously, investigators described an automated and reproducible method for analysis of TIL and investigators validated it for clinical use. Automated tests evaluating TIL are performed on virtual slides and have showed that, out of 1,220 tumours tested, 20% were highly infiltrated by CD3+ T cells. Patients presenting with a pMMR CRC with a high immune infiltrate had a better progression-free survival (HR=0.70; p=0.02). An immunoscore® described by Galon et al. has also a high prognostic value in CRC and is based on CD3+ and CD8+ T cells infiltration in the center and periphery of the tumour. Finally, approximately 14% of tumours with a high immune infiltrate have been found in patients with metastatic CRC.

Investigators formulated the hypothesis that patients with a pMMR CRC with a high immune infiltrate can be sensitive to ICI . Therefore, blocks of resected primary tumour will be collected and analysed prospectively. For each patient, slides containing tumour tissue and adjacent non-tumour tissue will be analysed using two techniques : immunoscore® and TuLIS score.It consist in Immunohistochemistry with CD3 and CD8 staining. Slides will be scanned and analysed by image analysis as previously described . Tumours will then be classified as having a "high" or "low" immune response according to type of lymphocyte infiltrate, which is independent of pre-analytic conditions. Only patients with a high immune response will be eligible for the POCHI trial. Other biomarkers will be analysed like other immune populations or mutational load. If investigators identify an immune score which seems clinically relevant to predict sensitivity to ICI in pMMR mCRC, this will make it possible to plan a randomised phase III trial comparing chemotherapy and anti-angiogenic antibody versus chemotherapy and anti-angiogenic antibody plus pembrolizumab in patients with a pMMR mCRC with a high immune score and/or a hypermutated genotype.

Investigators choose PFS at 10 months as primary endpoint in POCHI trial because it is a surrogate marker of OS. Actually median PFS in first-line setting with a doublet plus a biological agent is range from 8 to 11 months in unresectable mCRC, corresponding to a PFS of 50% at 10 months. The alternative clinical hypothesis to obtain 70% of patients alive and without progression at 10 months is ambitious and currently not achieved with current chemotherapies plus a biological agent. Up until now there is no data concerning survivals outcomes of patients with a MSS mCRC with high immune infiltration score.

03

Conditions studied

  • Colorectal Cancer Metastatic
  • High Immune Infiltrate
  • Microsatellite Stable

Keywords

  • immunotherapy
  • immune infiltrate
  • first line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • MSS and pMMR colorectal adenocarcinoma (metachronous or synchronous metastases), proven
  • Patients who have had chemotherapy ( or adjuvant) or radiotherapy (neo-adjuvant or adjuvant) for the treatment of primary tumor or metastatic resected disease R0 can be included if they have a recurrence more than 6 months after the end of this treatment.
  • High immune response defined as the immune infiltration scores obtained on the primary tumour (resection of primary tumour containing at least 2 mm of tumour-free margin between the tumour and non-tumour area)
  • Unresectable cancer with at least one measurable metastatic target according to v1.1 criteria
  • WHO PS ≤ 1
  • ≥ 3 months
  • Adequate haematological function: neutrophils ≥ 1,500 /mm3, ≥ 100,000/mm3, > 9 g/dL
  • Adequate liver function: /ALT ≤ 5xULN, total ≤ 2xULN, alkaline phosphatase. ≤ 5xULN
  • > 50 mL/min according to the formula
  • Proteinuria \<2+ (dipstick urinalysis) or ≤1g/24hour
  • Patient who is a beneficiary of the social security system
  • Information provided to patient and signature of the form

Exclusion criteria

Exclusion Criteria:

  • Active infection requiring intravenous antibiotics at day 1 of cycle 1
  • Active or untreated central nervous system
  • Another concomitant cancer or history of cancer during the last 5 years, except for carcinoma in situ of the uterine cervix or a basal cell or squamous cell skin carcinoma or any other carcinoma in situ considered as cured
  • Previous bone marrow allogenic stem cell transplantation or previous organ transplantation
  • History of idiopathic pulmonary fibrosis, medicinal product-related pneumonia or proof of active pneumonia or pneumonitis on a chest CT-scan prior to therapy
  • infection, active or C infection, active tuberculosis
  • Colorectal cancer with microsatellite instability (dMMR and/or MSI)
  • Patient eligible for curative treatment (resection and/or thermal ablation according to the opinion of the local multidisciplinary tumour meeting board)
  • Patient with only primary tumour available or only a sample of a metastasis (no surgical resection of the primary tumour)
  • Previous treatment with anti-PD1 or anti-PDL1 or another immunotherapy
  • An auto-immune disease which may worsen during treatment with an immune-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo or hyperthyroidism not requiring therapy are eligible)
  • Long-term immunosuppressant therapy (patients requiring therapy are eligible if administration at a dose ≤ 10 mg prednisone equivalent dose per day, administration of steroids by a route of administration resulting in minimal systemic exposure (cutaneous, rectal, ocular or inhalation) is authorised)
  • Known severe to monoclonal antibodies, to one of the medicinal products used or to one of the in the products used or a history of anaphylactic shock or of uncontrolled asthma
  • Vaccinations () within 30 days prior to start of treatment
  • Dihydropyrimidine Dehydrogenase (DPD) deficiency defined by uracilemy level ≥ 16 ng/mL
  • /QTc interval > 450 msec in men and > 470 msec in women
  • One of the following disorders during the 6 months prior to inclusion: myocardial infarction, unstable/severe angina pectoris, coronary artery bypass grafting, class II, III or IV congestive heart failure, stroke or
  • All uncontrolled progressive disorders during the last 6 months: hepatic insufficiency, renal insufficiency, respiratory insufficiency, arterial hypertension
  • History of an inflammatory digestive disease, obstruction or sub-obstruction not resolved with symptomatic treatment
  • Peptic ulcer disease not healed before the treatment
  • Not controlled HTA
  • Patient already enrolled in another therapeutic trial with an ongoing drug or whose treatment ended less than 4 weeks before inclusion
  • Absence of effective in patients (male and/or female patients) of , a pregnant or breastfeeding woman, women of childbearing potential and who have not had a pregnancy test
  • Impossibility to submit to medical follow-up of the trial due to geographic, social or psychological reasons
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Immunotherapy + chemotherapy

    Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.

    Drug: Capecitabine · Drug: Oxaliplatin · Drug: Bevacizumab · Drug: Pembrolizumab

Interventions

  • 2000 mg/m²/day, from day 1 to 14 of each cycle

  • 130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle

  • 7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle

  • 200 mg by IV infusion over 30 minutes, on day 1 of each cycle

06

What researchers measure

Primary outcomes

  1. The rate of patients alive and without progression at 10 months after inclusion

    Progression is evaluated by CT scan, according to RECIST criteria (version 1.1) definition by the investigator. Death was also considered as an event (all causes). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions compared the little sum of diameters observed during the study (NADIR), or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: 10 months after inclusion

Secondary outcomes

  1. Overall survival

    Overall survival is defined as the time from the date of the patient's inclusion to the patient's death (all causes). For alive patients the date of the latest news is taken into account

    Time frame: Up to 2 years after the end of the treatment

  2. Histological response in case of secondary resection

    Response evaluated according to the TRG (Rubbia-Brandt L et al. Annals Oncol 2007), for patients who underwent a secondary resection

    Time frame: Up to 2 years after the end of the treatment

07

Study locations

59 of 88 sites recruiting
  • Ch - Centre Hospitalier D'Abbeville
    Abbeville, 80090, France
    Not yet recruiting
  • Chu - Hôpital Sud
    Amiens, France
    Recruiting
  • Privé - Clinique de L'Europe
    Amiens, France
    Not yet recruiting
  • Privé - Ico - Site Paul Papin
    Angers, 49055, France
    Not yet recruiting
  • Privé - Hôpital Privé Pays de Savoie
    Annemasse, 74100, France
    Not yet recruiting
  • Privé - Hôpital Privé D'Antony
    Antony, 92160, France
    Recruiting
  • Ch - Hôpital Henri Duffaut
    Avignon, 84902, France
    Recruiting
  • Prive - Institut Du Cancer Avignon Provence
    Avignon, France
    Recruiting
    • Rania BOUSTANY-GRENIER · Contactr.boustany@isc84.org · 0490276262
    • Laurent MINEUR · Contactl.mineur@isc84.org · 0490276181
    • Rania BOUSTANY-GRENIER · Sub investigator
    • Laurent MINEUR · Sub investigator
  • Ch - Centre Hospitalier de La Côte Basque
    Bayonne CEDEX, 64100, France
    Recruiting
  • Privé - Clinique Capio Balharra
    Bayonne, France
    Not yet recruiting
  • Ch - Centre Hospitalier de Beauvais
    Beauvais, 60021, France
    Not yet recruiting
  • Chu - Hôpital Jean Minjoz
    Besançon, 25030, France
    Not yet recruiting
  • Privé - Polyclinique Bordeaux Nord
    Bordeaux CEDEX, 33077, France
    Recruiting
  • Privé - Cac - Clinique Bergonié
    Bordeaux, 33076, France
    Recruiting
  • Privé - Clinique Tivoli
    Bordeaux, France
    Recruiting
  • Ch - Hôpital Duchenne
    Boulogne-sur-Mer, France
    Recruiting
  • Chu - Hôpital Ambroise Paré - Service Anatomie Pathologique
    Boulogne, France
    Recruiting
  • Chu - Hôpital Morvan - Institut de Cancérologie
    Brest, 29609, France
    Recruiting
  • Privé - Clinique Pasteur Lanroze Cfro
    Brest, France
    Recruiting
  • Ch - Centre Hospitalier de Béziers
    Béziers, France
    Recruiting
  • Privé - Centre Maurice Tubiana
    Caen, 14000, France
    Not yet recruiting
    • Emmanuel SEVIN, Dr · Contacte.sevin@i-l-c.fr · +33 2 31 82 84 62
    • Khadija JALALI, Dr · Contactk-jalali@i-l-c.fr · 0231522000
    • Emmanuel SEVIN, Dr · Principal investigator
  • Privé - Cac - Centre Francois Baclesse
    Caen, 14076, France
    Recruiting
  • Prive - Polyclinique Du Parc Caen
    Caen, France
    Not yet recruiting
    • Emmanuel SEVIN · Contact0231522000
    • Khadija JALALI · Contact0231522000
    • Emmanuel SEVIN · Principal investigator
    • Khadija JALALI · Sub investigator
  • Privé - Infirmerie Protestante de Lyon
    Caluire-et-Cuire, 69300, France
    Not yet recruiting
  • Privé - Médipole de Savoie
    Challes-les-Eaux, 73190, France
    Not yet recruiting
  • Privé - Hôpital Privé Paul D'Egine
    Champigny-sur-Marne, 94500, France
    Recruiting
    • Adil CHAFAI EL ALAOUI, Dr · Contactadil.alaoui@gmail.com · +33 1 49 83 64 05
    • Fadila DEMIL, Dr · Contactfadoc13@hotmail.com · +33 1 49 83 64 05
    • Adil CHAFAI EL ALAOUI, Dr · Principal investigator
  • Ch - Centre Hospitalier de Cholet
    Cholet, 49300, France
    Recruiting
  • Chu - Hôpital Estaing
    Clermont Ferrand, France
    Recruiting
  • Ch - Hôpitaux Civils de Colmar
    Colmar, 68024, France
    Not yet recruiting
  • Privé - Clinique Saint Come
    Compiègne CEDEX, 60204, France
    Not yet recruiting
  • Privé - Clinique de Flandre
    Coudekerque-Branche, 59210, France
    Recruiting
  • Ch - Ghpso - Site de Creil
    Creil, 60100, France
    Not yet recruiting
  • Chu - Hôpital Henri Mondor
    Créteil CEDEX, 94000, France
    Recruiting
  • Ch - Chic de Créteil
    Créteil, France
    Not yet recruiting
  • Chu - Hôpital François Mitterrand
    Dijon CEDEX, 21079, France
    Recruiting
  • Privé - Cac - Centre Georges-Francois Leclerc
    Dijon, 21079, France
    Not yet recruiting
    • François GHIRINGHELLI, Pr · Contactfghiringhelli@cgfl.fr · +33 3 80 73 75 28
    • Julie VINCENT, Dr · Contactjvincent@cgfl.fr · 0380737528
    • François GHIRINGHELLI, Pr · Principal investigator
  • Privé - Polyclinique de Blois - 3Eme Etage
    La Chaussee St Victor, 41260, France
    Recruiting
  • Ch - Chd Vendée
    La Roche-sur-Yon, 85925, France
    Recruiting
  • CH - GROUPE HOSPITALIER DE La Rochelle RE AUNIS
    La Rochelle, France
    Recruiting
  • Privé - Hôpital Franco Britannique
    Levallois-Perret, France
    Recruiting
  • Privé - Clinique Du Bois
    Lille, France
    Not yet recruiting
  • Chu - Centre Hospitalier Dupuytren
    Limoges, 87042, France
    Recruiting
  • Ch - Chbs - Hôpital Du Scorff
    Lorient CEDEX, 56322, France
    Recruiting
  • Privé - Hôpital Jean Mermoz
    Lyon, 69008, France
    Recruiting
  • Privé - Hôpital Europeen
    Marseille CEDEX 03, 13331, France
    Recruiting
  • Chu - Hôpital La Timone
    Marseille CEDEX 5, 13385, France
    Not yet recruiting
  • Privé - Hôpital Saint Joseph
    Marseille, 13008, France
    Recruiting
  • Privé - Haliodx
    Marseille, France
    Recruiting
  • Ch - Ghi - Groupe Hospitalier de L'Est Francilien - Site de Meaux
    Meaux, 77100, France
    Recruiting
  • Ch - Hôpital Layné
    Mont-de-Marsan, 40 000, France
    Recruiting
  • Privé - Centre Azureen de Cancerologie
    Mougins, 06250, France
    Recruiting
  • Privé - Hôpital Prive Arnault Tzanck
    Mougins, 06250, France
    Recruiting
  • Privé - Polyclinique de Gentilly
    Nancy, 54100, France
    Not yet recruiting
    • Fabien BROCARD, Dr · Contactf.brocard@oncog.fr · +33 3 83 93 50 05
    • Laurène GAVOILLE, Dr · Contactl.gavouille@oncog.fr · +33 3 83 93 50 05
    • Fabien BROCARD, Dr · Principal investigator
  • Chu - Hôpital Carémeau
    Nîmes, 30029, France
    Recruiting
  • Privé - Institut Mutualiste Montsouris
    Paris, 75014, France
    Recruiting
  • Chu - Hôpital Europeen Georges Pompidou
    Paris, 75015, France
    Recruiting
  • Privé - Groupe Hospitalier Diaconesses Croix Saint Simon
    Paris, 75020, France
    Recruiting
  • Chu - Hôpital Saint Antoine
    Paris, France
    Not yet recruiting
  • Chu - Hôpital Saint-Louis
    Paris, France
    Not yet recruiting
  • Ch - Centre Hospitalier de Pau
    Pau CEDEX, 64046, France
    Recruiting
  • Privé - Polyclinique Francheville
    Perigueux, 24004, France
    Recruiting
  • Ch - Centre Hospitalier Saint-Jean
    Perpignan, France
    Recruiting
  • Chu - Hôpital Haut Lévêque
    Pessac, France
    Not yet recruiting
  • Chu Lyon Sud - Pierre Benite
    Pierre-Bénite, 69495, France
    Recruiting
  • Privé - Centre Cario Hpca
    Plérin, France
    Recruiting
  • Chu - Centre Hospitalier Universitaire de Poitiers - La Miletrie
    Poitiers, 86021, France
    Recruiting
  • Ch - Chic de Quimper
    Quimper, France
    Recruiting
  • Chu - Centre Hospitalier Universitaire Robert Debre
    Reims CEDEX, 51092, France
    Recruiting
  • Privé - Cac - Institut Jean Godinot
    Reims, 51726, France
    Recruiting
  • Chu - Centre Hospitalier Universitaire Pontchaillou
    Rennes CEDEX 9, 35033, France
    Recruiting
  • Ch - Hôpital Drome Nord
    Romans-sur-Isère, 26100, France
    Recruiting
  • Privé - Clinique Saint-Grégoire
    Saint-Grégoire, France
    Recruiting
  • Privé - Cac - Ico - Site René Gauducheau
    Saint-Herblain, 44805, France
    Not yet recruiting
  • Ch - Centre Hospitalier de Saint-Malo
    Saint-Malo, 35403, France
    Recruiting
  • Chu - Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord - Service Hge
    Saint-Priest-en-Jarez, 42270, France
    Recruiting
  • Privé - Polyclinique Saint-Claude
    Saint-Quentin, 02100, France
    Not yet recruiting
  • Privé - Clinique Charcot
    Sainte-Foy-lès-Lyon, 69510, France
    Not yet recruiting
  • Privé - Clinique Sainte Anne
    Strasbourg, 67000, France
    Recruiting
  • Privé - Cac - Paul Strauss / Institut de Cancérologie de Strasbourg Europe
    Strasbourg, 67065, France
    Recruiting
  • Chu - Hôpital Foch
    Suresnes, 92151, France
    Not yet recruiting
  • Privé - Polyclinique de L'Ormeau
    Tarbes, 65000, France
    Not yet recruiting
  • Ch - Hôpital Sainte Musse
    Toulon, 83000, France
    Recruiting
  • Chu - Hôpital Trousseau
    Tours CEDEX 9, 37044, France
    Recruiting
  • Ch - Centre Hospitalier de Valenciennes
    Valenciennes, 59300, France
    Not yet recruiting
  • Privé - Cac - Institut de Cancerologie de Lorraine
    Vandœuvre-lès-Nancy, 54519, France
    Recruiting
  • Chu - Hôpital Bradois
    Vandœuvre-lès-Nancy, France
    Recruiting
  • Chu - Hôpital Paul Brousse
    Villejuif, 94804, France
    Not yet recruiting
  • Privé - Cac - Institut Gustave Roussy
    Villejuif, France
    Recruiting
08

References and documents

Publications

  • Carbonnel F, Soularue E, Coutzac C, Chaput N, Mateus C, Lepage P, Robert C. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol. 2017 Apr;39(3):327-331. doi: 10.1007/s00281-016-0613-x. Epub 2017 Jan 16. PubMed 28093620 ↗
  • Caulet M, Lecomte T, Bouche O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Leger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet. 2016 Nov;55(11):1381-1394. doi: 10.1007/s40262-016-0406-3. PubMed 27312193 ↗
  • Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219. PubMed 22722843 ↗
  • Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245. PubMed 22419253 ↗
  • Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2. PubMed 29097493 ↗
  • Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001 Feb 1;19(3):843-50. doi: 10.1200/JCO.2001.19.3.843. PubMed 11157038 ↗
  • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. PubMed 25428504 ↗
  • Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10. PubMed 28397821 ↗
  • Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9. PubMed 28280249 ↗
  • Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9. PubMed 27158904 ↗
  • Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156. PubMed 22722830 ↗
  • Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18. PubMed 25797516 ↗
  • Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821. PubMed 20203603 ↗
  • Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragon L, Jacquelot N, Qu B, Ferrere G, Clemenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. PubMed 29097494 ↗
  • Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37. doi: 10.1038/nrc3066. Epub 2011 May 12. PubMed 21562580 ↗
  • Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3. PubMed 26843508 ↗
  • Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001 Nov;313(1-2):139-42. doi: 10.1016/s0009-8981(01)00665-9. PubMed 11694251 ↗
  • Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23. PubMed 24658074 ↗
  • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954. PubMed 25428505 ↗
  • Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537. PubMed 24264990 ↗
  • Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. PubMed 23539594 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Sep 2024, 41 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 41 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2020
First posted
Feb 10, 2020
StartActual
Apr 6, 2021
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04262687
Lead sponsor
Federation Francophone de Cancerologie Digestive
Responsible party
Sponsor
First posted
Feb 10, 2020
Start date
Apr 6, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Aug 18, 2023

Study contacts

Jeremie BEZ
Contact
jeremie.bez@u-bourgogne.fr
0380393483
David TOUGERON, MD,PHD
principal investigator · CHU Poitiers

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion